[Use of ursodeoxycholic acid in treatment of chronic hepatitis C]

HCV infection often results in chronic hepatitis (40-60% of patients). Interferon-alfa therapy induce complete remissions in around 25% of patients and temporary remissions in another 50% of cases. Because of low efficiency of this therapy, the combination therapy is still finding. The combination of interferon-alfa and ursodeoxycholic acid prolongs the efficacy of interferon-alfa in chronic hepatitis C by delaying the probability of biochemical relapse and/or by reducing its severity, without effecting HCV viremia.